# A Study Comparing Four Different Rivoceranib Tablets in Healthy Participants

> **NCT05287360** · PHASE1 · COMPLETED · sponsor: **Elevar Therapeutics** · enrollment: 60 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Rivoceranib

## Key facts

- **NCT ID:** NCT05287360
- **Lead sponsor:** Elevar Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-12-30
- **Primary completion:** 2022-03-16
- **Final completion:** 2022-03-24
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2022-04-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05287360

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05287360, "A Study Comparing Four Different Rivoceranib Tablets in Healthy Participants". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05287360. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*